Australia
Biotome Pty Ltd: Biotome is an Australian biotechnology startup founded in 2017, specializing in next-generation antibody diagnostics. The company's slogan, "Next generation antibody diagnostics," reflects its core focus on developing antibody tests using advanced technology and precision immunology to revolutionize traditional serology tests.
The company's proprietary antibody tests offer enhanced precision and more detailed disease information compared to existing screening methods. Biotome's innovative approach involves an efficient and scalable process for discovering precision markers for diagnosis, applicable to a wide range of diseases triggering an immune response. The development and utilization of patentable peptide markers are fundamental to Biotome's commercialization process, securing the company's position in a market largely dominated by lower-accuracy, non-proprietary tests from major corporations.
Furthermore, Biotome proactively extends its expertise in marker identification, patenting, and precision immunology data analytics to research companies and organizations, positioning itself as a leader in the field. The company's commitment to advanced technology and precision diagnostics has garnered the attention of investors.
The most recent influx of funding for Biotome came in the form of a Non Equity Assistance investment on 07 June 2023, with MedTech Innovator participating as the investor. This investment is indicative of the growing interest and support for Biotome's groundbreaking work in the biotechnology and healthcare industries.
